Latest NeuroSense Therapeutics News & Updates

See the latest news and media coverage for NeuroSense Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
NeuroSense Therapeutics

Clinical-stage biotech developing neurodegenerative disease treatments

neurosense-tx.com
Headquarters
Cambridge, United States
Founded year
2017
Company type
Public company
Number of employees
30–50

Latest news about NeuroSense Therapeutics

Company announcements

  • NeuroSense Therapeutics

    NeuroSense announces pricing of insider-led PIPE financing

    The $600,000 private placement involves 750,000 shares at $0.80 each, led by CEO and CFO. Proceeds fund general corporate purposes.

  • NeuroSense Therapeutics

    NeuroSense receives Brazilian patent for PrimeC

    The patent protects the composition through October 2042, following U.S. and Australian grants, strengthening global IP for ALS and Alzheimer's treatments.

  • NeuroSense Therapeutics

    NeuroSense Therapeutics receives Nasdaq notifications

    The Company is not in compliance with minimum bid price and market value requirements. Nasdaq grants until September 29, 2026, to regain compliance. Trading continues unaffected.

  • NeuroSense Therapeutics

    NeuroSense Therapeutics reports 2025 financial results

    Reports $11.1M net loss, $0.2M cash, PrimeC Phase 3 FDA clearance in ALS, survival benefits, and upcoming milestones.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about NeuroSense Therapeutics

Track NeuroSense Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

NeuroSense Therapeutics competitors & trending companies

Browse news for competitors to NeuroSense Therapeutics and other trending companies.